---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-081982"
form_type: "8-K"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:39:57.751242+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pasithea reports positive Phase 1 data for PAS-004: no TRAEs, prolonged stable disease in colon cancer patient

## Summary
- No treatment-related adverse events or dose-limiting toxicities observed in first 2 cohorts (n=6); no rash or GI toxicity.
- Heavily pre-treated stage 3 colon cancer patient (BRAF K601E) achieved prolonged stable disease, remains on drug into 6th cycle.
- Half-life ~70 hours supports once-daily or less frequent oral dosing; steady-state Cmax/Cmin ratio of 1.2.
- Systemic exposure at steady-state enables constant target inhibition while avoiding peak plasma toxicities.
- Safety review completed; cohort 3 dosing initiated at 8 mg with protocol amendment to increase dosing schedule.

## SEC filing metadata
- accession: 0001213900-24-081982
- form_type: 8-K
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390024081982/0001213900-24-081982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390024081982/ea0215731-8k_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-081982
- JSON: https://secwatch.observer/filing/0001213900-24-081982.json
- Plain text: https://secwatch.observer/filing/0001213900-24-081982.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.